1. Introduction {#sec1-jcm-08-00981}
===============

Extracorporeal membrane oxygenation (ECMO), as a mechanical circulatory support system, is utilized as a treatment for cardiovascular or respiratory failure \[[@B1-jcm-08-00981],[@B2-jcm-08-00981],[@B3-jcm-08-00981]\]. There are two main types of ECMO, including venovenous (VV)-ECMO for patients with isolated respiratory failure and venoarterial (VA)-ECMO for combined severe cardiac and respiratory failure \[[@B4-jcm-08-00981]\]. Over the past 40 years, the clinical applications and feasibility of ECMO have expanded in patients with refractory cardiorespiratory failure, and there has been an exponential increase in the number of centers utilizing ECMO globally \[[@B3-jcm-08-00981],[@B5-jcm-08-00981],[@B6-jcm-08-00981],[@B7-jcm-08-00981],[@B8-jcm-08-00981],[@B9-jcm-08-00981]\]. Studies have demonstrated survival benefits of ECMO ranging from 20% to 50% in patients with cardiac arrest, severe adult respiratory distress syndrome (ARDS), and refractory cardiogenic shock \[[@B5-jcm-08-00981],[@B10-jcm-08-00981],[@B11-jcm-08-00981],[@B12-jcm-08-00981],[@B13-jcm-08-00981],[@B14-jcm-08-00981],[@B15-jcm-08-00981],[@B16-jcm-08-00981]\].

Despite these benefits, there have been a number of reports to highlight the concomitant occurrence of organ failures and complications including acute kidney injury (AKI), infections, thrombosis, bleeding and coagulopathy, and neurological events \[[@B17-jcm-08-00981],[@B18-jcm-08-00981]\]. The underlying mechanisms for AKI among patients requiring ECMO appear to be complex and include hemodynamic instabilities, inflammatory responses, coagulation-platelet abnormalities, and immune-mediated injury that arise from the primary underlying disease, premorbid conditions and the ECMO circuit \[[@B18-jcm-08-00981],[@B19-jcm-08-00981],[@B20-jcm-08-00981],[@B21-jcm-08-00981],[@B22-jcm-08-00981],[@B23-jcm-08-00981],[@B24-jcm-08-00981],[@B25-jcm-08-00981],[@B26-jcm-08-00981],[@B27-jcm-08-00981],[@B28-jcm-08-00981]\]. Due to previously non-uniform definitions of AKI, the reported incidences of AKI among patients requiring ECMO therapy ranged widely from 8% up to 85% \[[@B4-jcm-08-00981],[@B7-jcm-08-00981],[@B15-jcm-08-00981],[@B18-jcm-08-00981],[@B19-jcm-08-00981],[@B20-jcm-08-00981],[@B21-jcm-08-00981],[@B22-jcm-08-00981],[@B23-jcm-08-00981],[@B24-jcm-08-00981],[@B25-jcm-08-00981],[@B26-jcm-08-00981],[@B27-jcm-08-00981],[@B28-jcm-08-00981],[@B29-jcm-08-00981],[@B30-jcm-08-00981],[@B31-jcm-08-00981],[@B32-jcm-08-00981],[@B33-jcm-08-00981],[@B34-jcm-08-00981],[@B35-jcm-08-00981],[@B36-jcm-08-00981],[@B37-jcm-08-00981],[@B38-jcm-08-00981],[@B39-jcm-08-00981],[@B40-jcm-08-00981],[@B41-jcm-08-00981],[@B42-jcm-08-00981],[@B43-jcm-08-00981],[@B44-jcm-08-00981],[@B45-jcm-08-00981],[@B46-jcm-08-00981],[@B47-jcm-08-00981],[@B48-jcm-08-00981],[@B49-jcm-08-00981],[@B50-jcm-08-00981],[@B51-jcm-08-00981],[@B52-jcm-08-00981],[@B53-jcm-08-00981],[@B54-jcm-08-00981],[@B55-jcm-08-00981],[@B56-jcm-08-00981],[@B57-jcm-08-00981],[@B58-jcm-08-00981],[@B59-jcm-08-00981],[@B60-jcm-08-00981],[@B61-jcm-08-00981],[@B62-jcm-08-00981],[@B63-jcm-08-00981],[@B64-jcm-08-00981],[@B65-jcm-08-00981],[@B66-jcm-08-00981],[@B67-jcm-08-00981],[@B68-jcm-08-00981],[@B69-jcm-08-00981],[@B70-jcm-08-00981]\]. In addition, the incidence and mortality associated with AKI in patients requiring ECMO and their trends remain unclear.

This systematic review was conducted with the aim to summarize the incidence (using standard AKI definitions) and the impact of AKI on mortality risk among adult patients on ECMO.

2. Methods {#sec2-jcm-08-00981}
==========

2.1. Information Sources and Search Strategy {#sec2dot1-jcm-08-00981}
--------------------------------------------

The protocol for this systematic review and meta-analysis is registered with International Prospective Register of Systematic Reviews (PROSPERO no. CRD42018103527). A systematic literature review of EMBASE, Ovid MEDLINE, and the Cochrane Database of Systematic Reviews from database inception through March 2019 was conducted to summarize the incidence and impact of AKI on mortality risk among adult patients on ECMO. Two authors (C.T. and W.C.) independently performed a systematic literature search utilizing a search approach that consolidated the search terms "extracorporeal membrane oxygenation" OR "ECMO" AND "acute kidney injury" OR "acute renal failure." Further details regarding the search strategy utilized for each database are provided in Online [Supplementary Data 1](#app1-jcm-08-00981){ref-type="app"}. No language restriction was implemented. A manual search for conceivably related articles utilizing references of the included studies was additionally performed. This systematic review was performed following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) statement \[[@B71-jcm-08-00981]\].

2.2. Study Selection {#sec2dot2-jcm-08-00981}
--------------------

Studies were included in this systematic review if they were clinical trials or observational studies that reported the incidence of AKI (using standard AKI definitions including RIFLE (Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease) \[[@B72-jcm-08-00981]\], AKIN (Acute Kidney Injury Network) \[[@B73-jcm-08-00981]\], and KDIGO (Kidney Disease: Improving Global Outcomes) classifications) \[[@B74-jcm-08-00981]\], severe AKI requiring renal replacement therapy (RRT), and mortality risk of AKI among adult patients (age ≥ 18 years old) on ECMO. Eligible studies needed to provide the data to evaluate the incidence or mortality rate of AKI with 95% confidence intervals (CI). Retrieved articles were independently examined for eligibility by the two authors (C.T. and W.C.). Inconsistencies were discussed and resolved by shared agreement. The size of the study did not limit inclusion.

2.3. Data Collection Process {#sec2dot3-jcm-08-00981}
----------------------------

A structured data collecting form was adopted to gather the following data from individual study including title, name of authors, publication year, year of the study, country where the study was conveyed, type of ECMO, AKI definition, incidence of AKI, incidence of severe AKI requiring RRT, and mortality risk of AKI among patients on ECMO.

2.4. Statistical Analysis {#sec2dot4-jcm-08-00981}
-------------------------

We used the Comprehensive Meta-Analysis software version 3.3.070 (Biostat Inc, Englewood, NJ, USA) to conduct the meta-analysis. Adjusted point estimates of included studies were consolidated by the generic inverse variance method of DerSimonian-Laird, which assigned the weight of individual study based on its variance \[[@B75-jcm-08-00981]\]. Due to the probability of between-study variance, we applied a random-effects model to pool outcomes of interest, including the incidence of AKI and mortality risk. Statistical heterogeneity of studies was assessed by the Cochran's Q test (*p* \< 0.05 for a statistical significance) and the *I*^2^ statistic (≤25%: insignificant heterogeneity, 26%--50%: low heterogeneity, 51%--75%: moderate heterogeneity and ≥75%: high heterogeneity) \[[@B76-jcm-08-00981]\]. The presence of publication bias was evaluated by both the funnel plot and the Egger test \[[@B77-jcm-08-00981]\].

3. Results {#sec3-jcm-08-00981}
==========

A total of 1,632 potentially eligible articles were identified with our search approach. After excluding 644 articles that were either in-vitro studies, focused on pediatric patient population, animal studies, case reports, correspondences, or review articles, and 831 articles due to being duplicates, 157 articles remained for full-length article review. Seventy-three articles were subsequently excluded as they did not provide data on the incidence of AKI or mortality of AKI, while 33 articles were excluded because they were not clinical trials or observational studies. Ten studies \[[@B19-jcm-08-00981],[@B20-jcm-08-00981],[@B21-jcm-08-00981],[@B22-jcm-08-00981],[@B23-jcm-08-00981],[@B24-jcm-08-00981],[@B25-jcm-08-00981],[@B26-jcm-08-00981],[@B27-jcm-08-00981],[@B28-jcm-08-00981]\] were additionally excluded because they did not use a standard AKI definition or did not report the incidence of severe AKI requiring RRT. Therefore, 41 cohort studies \[[@B7-jcm-08-00981],[@B15-jcm-08-00981],[@B29-jcm-08-00981],[@B30-jcm-08-00981],[@B31-jcm-08-00981],[@B32-jcm-08-00981],[@B33-jcm-08-00981],[@B34-jcm-08-00981],[@B35-jcm-08-00981],[@B36-jcm-08-00981],[@B37-jcm-08-00981],[@B38-jcm-08-00981],[@B39-jcm-08-00981],[@B40-jcm-08-00981],[@B41-jcm-08-00981],[@B42-jcm-08-00981],[@B43-jcm-08-00981],[@B44-jcm-08-00981],[@B45-jcm-08-00981],[@B46-jcm-08-00981],[@B47-jcm-08-00981],[@B48-jcm-08-00981],[@B49-jcm-08-00981],[@B50-jcm-08-00981],[@B51-jcm-08-00981],[@B52-jcm-08-00981],[@B53-jcm-08-00981],[@B54-jcm-08-00981],[@B55-jcm-08-00981],[@B56-jcm-08-00981],[@B57-jcm-08-00981],[@B58-jcm-08-00981],[@B59-jcm-08-00981],[@B60-jcm-08-00981],[@B61-jcm-08-00981],[@B62-jcm-08-00981],[@B63-jcm-08-00981],[@B64-jcm-08-00981],[@B65-jcm-08-00981],[@B66-jcm-08-00981],[@B67-jcm-08-00981]\] with a total of 10,282 adult patients receiving ECMO were enrolled. The systematic review of the literature flowchart is demonstrated in [Figure 1](#jcm-08-00981-f001){ref-type="fig"}. The characteristics of the included studies are shown in [Table 1](#jcm-08-00981-t001){ref-type="table"}.

3.1. Incidence of AKI in Patients Requiring ECMO {#sec3dot1-jcm-08-00981}
------------------------------------------------

Overall, the pooled estimated incidence of AKI and severe AKI requiring RRT while on ECMO were 62.8% (95%CI: 52.1%--72.4%, *I*^2^ = 94%, [Figure 2](#jcm-08-00981-f002){ref-type="fig"}A) and 44.9% (95%CI: 40.8%-49.0%, *I*^2^ = 91%, [Figure 2](#jcm-08-00981-f002){ref-type="fig"}B), respectively. Subgroup analyses were performed according to AKI definitions. The pooled estimated incidence rates of AKI by RIFLE, AKIN, and KDIGO criteria were 67.5% (95%CI: 43.9%--84.6%, *I*^2^ = 85%), 57.8% (95%CI: 44.6%--70.0%, *I*^2^ = 86%), and 68.2% (95%CI: 43.8%--85.55%, *I*^2^ = 98%), respectively.

Subgroup analysis based on the type of ECMO was also performed. Pooled estimated incidence of AKI and severe AKI requiring RRT while on venoarterial (VA)-ECMO were 60.8% (95%CI: 32.9%--83.1%, *I*^2^ = 96%) and 49.5% (95%CI: 39.6%--59.4%, *I*^2^ = 90%), respectively. Pooled estimated incidence of AKI and severe AKI requiring RRT while on venovenous (VV)-ECMO were 45.7% (95%CI: 33.2%--58.8%, *I*^2^ = 47%) and 37.0% (95%CI: 14.8%--66.5%, *I*^2^ = 95%), respectively. Meta-regression showed that year of the study did not significantly affect the incidence of AKI (*p* = 0.67) or AKI requiring RRT (*p* = 0.83), as shown in [Figure 3](#jcm-08-00981-f003){ref-type="fig"}.

3.2. AKI associated Mortality in Patients Requiring ECMO {#sec3dot2-jcm-08-00981}
--------------------------------------------------------

Mortality rate and mortality risk associated with AKI in patients requiring ECMO are demonstrated in [Table 1](#jcm-08-00981-t001){ref-type="table"} and [Table 2](#jcm-08-00981-t002){ref-type="table"}, respectively. The pooled estimated hospital and/or 90-day mortality rates of patients with AKI and severe AKI requiring RRT while on ECMO were 62.0% (95%CI: 54.7%--68.8%, *I*^2^ = 73%, [Figure 4](#jcm-08-00981-f004){ref-type="fig"}A) and 68.4% (95%CI: 62.6%--73.6%, *I*^2^ = 87%, [Figure 4](#jcm-08-00981-f004){ref-type="fig"}B), respectively.

The pooled OR of hospital mortality among patients receiving ECMO with AKI on RRT was 3.73 (95% CI, 2.87--4.85, *I*^2^ = 62%, [Figure 5](#jcm-08-00981-f005){ref-type="fig"}A). When the analysis was limited to studies with confounder-adjusted analysis, the increased hospital mortality remained significant among patients receiving ECMO with AKI requiring RRT with pooled OR of 3.32 (95% CI, 2.21--4.99, *I*^2^ = 82%, [Figure 5](#jcm-08-00981-f005){ref-type="fig"}B).

Meta-regression showed that year of the study did not significantly affect hospital mortality among patients receiving ECMO with AKI requiring RRT (*p* = 0.86), as shown in [Figure 6](#jcm-08-00981-f006){ref-type="fig"}.

3.3. Evaluation for Publication Bias {#sec3dot3-jcm-08-00981}
------------------------------------

Funnel plots ([Figure 7](#jcm-08-00981-f007){ref-type="fig"}) and Egger's regression asymmetry tests were utilized to assess for publication bias in our meta-analyses evaluating the incidence of AKI and severe AKI requiring RRT while on ECMO. There was no publication bias as determined by the funnel plot and Egger's regression asymmetry test with *p* = 0.62 and *p* = 0.17 for the incidence of AKI and severe AKI requiring RRT, respectively.

4. Discussion {#sec4-jcm-08-00981}
=============

The findings of our meta-analysis demonstrate that patients who required ECMO had incidence rates of AKI (using standard AKI definitions) and severe AKI requiring RRT of 62.8% and 44.9%, respectively. Moreover, patients with AKI and severe AKI requiring RRT had high associated mortality rates of 62.0% and 68.4%, respectively.

Although the mechanisms underlying ECMO associated-AKI remains unclear, it is likely complex and multifactorial, including contributing factors such as primary disease progression, altered hemodynamics, low cardiac output syndrome, exposure to nephrotoxic agents (for management of underlying diseases), new-onset sepsis, high intrathoracic pressures, fluid overload, ischemia-reperfusion injury, release of proinflammatory mediators and oxidative stress, hemolysis and iron-mediated (hemoglobin-induced) renal injury, and hypercoagulable state resulting in renal microembolisms \[[@B4-jcm-08-00981],[@B8-jcm-08-00981],[@B68-jcm-08-00981],[@B78-jcm-08-00981],[@B79-jcm-08-00981]\]. Studies have demonstrated the activation of proinflammatory mediators such as tumor necrosis factor-alpha (TNF-α), interleukins (e.g., IL-1β, IL-6, IL-8) and other cytokine signaling cascades due to the continuous exposure of blood to non-biological and non-endothelialized ECMO interface \[[@B68-jcm-08-00981],[@B80-jcm-08-00981],[@B81-jcm-08-00981]\]. Activation of the inflammatory cascades can result in hyperdynamic vasodilated hypotensive states, leading to AKI \[[@B68-jcm-08-00981],[@B78-jcm-08-00981]\].

Following the initiation of ECMO treatment, there are improvements in oxygenation and oxygen consumption as well as hemodynamics \[[@B3-jcm-08-00981],[@B5-jcm-08-00981],[@B6-jcm-08-00981],[@B7-jcm-08-00981],[@B8-jcm-08-00981],[@B9-jcm-08-00981]\]. However, ischemia-reperfusion injury can also occur after the restoration of circulation to previously hypoxic cells and hypoperfused organs, leading to the production of reactive oxygen species (ROS) and oxidative stress-mediated injury \[[@B68-jcm-08-00981],[@B78-jcm-08-00981]\]. In addition, ECMO-associated complications or adverse effects such as hemolysis, hemorrhage or thrombosis also can play important roles in the development of AKI \[[@B29-jcm-08-00981],[@B68-jcm-08-00981],[@B82-jcm-08-00981],[@B83-jcm-08-00981],[@B84-jcm-08-00981]\]. Despite the advance of a new miniaturized ECMO system, hemolysis due to shear stress from the ECMO circuit has been reported among ECMO patients with incidences between 5% and 18% \[[@B17-jcm-08-00981],[@B85-jcm-08-00981],[@B86-jcm-08-00981],[@B87-jcm-08-00981]\]. This can contribute to heme pigment-induced AKI \[[@B83-jcm-08-00981],[@B84-jcm-08-00981]\]. Although improvements in the ECMO technology have led to less thrombus development in its circuit with an improved capacity of the circuit to remove large emboli \[[@B68-jcm-08-00981],[@B82-jcm-08-00981]\], smaller thrombi can still develop and result in renal microembolism \[[@B68-jcm-08-00981],[@B82-jcm-08-00981]\], particularly with VA-ECMO \[[@B82-jcm-08-00981]\].

The type of ECMO may also differently affect AKI risk. Our study demonstrated a higher incidence of AKI among patients requiring VA-ECMO (60.8%) than those requiring VV-ECMO (45.7%). While VV-ECMO is typically utilized for patients with isolated respiratory failure, VA-ECMO is used for combined severe cardiac and respiratory failure \[[@B4-jcm-08-00981]\]. In VA-ECMO, there is a mixture of pulsatile arterial flow from the native heart and non-pulsatile arterial flow from the ECMO pump. Conversely, VV-ECMO maintains pulsatile cardiac output, and alterations in renal perfusion may conceivably be smaller \[[@B4-jcm-08-00981]\]. Recent studies have shown that pulsatile flow may provide beneficial effects over non-pulsatile flow, especially protective effects on microcirculation and renal perfusion \[[@B88-jcm-08-00981],[@B89-jcm-08-00981],[@B90-jcm-08-00981]\]. The differences in patient population and pulsatility between the two types of ECMO are likely explanations underlying the higher AKI incidence among patients requiring VA-ECMO.

As there is no treatment available for AKI, management of AKI is limited to appropriate secondary preventive measures and supportive strategies \[[@B91-jcm-08-00981],[@B92-jcm-08-00981],[@B93-jcm-08-00981],[@B94-jcm-08-00981],[@B95-jcm-08-00981],[@B96-jcm-08-00981]\]. RRT in the form of continuous renal replacement therapy (CRRT) is often required among patients requiring ECMO with severe AKI \[[@B42-jcm-08-00981],[@B55-jcm-08-00981],[@B97-jcm-08-00981]\]. Our study demonstrated no significant correlation between the year of study and the incidence of AKI and/or severe AKI requiring RRT despite considerable changes in technology and practice of ECMO among adult patients. Furthermore, we showed a 3.7-fold increased risk of hospital mortality among ECMO patients with severe AKI requiring RRT. Thus, prevention and early identification of AKI among patients at-risk of ECMO-associated AKI could potentially play a crucial role in improved survival. Studies have shown several important AKI risk factors among patients requiring ECMO including older age, elevated lactate levels before ECMO initiation, high dose of inotropic drugs, severely reduced left ventricular ejection fraction, cirrhosis, postcardiotomy shock as an indication for ECMO, and finally ECMO pump speed and its duration \[[@B56-jcm-08-00981],[@B64-jcm-08-00981],[@B67-jcm-08-00981]\]. Lee et al. recently observed a lower AKI association with a higher ECMO pump speed \[[@B56-jcm-08-00981]\]. Although the underlying pathophysiology remains unclear, excessive ECMO pump speed has been shown to induce hemolysis and complement activation in vitro and animal model \[[@B98-jcm-08-00981],[@B99-jcm-08-00981]\]. In pediatric patients receiving ECMO, Lou et al. also demonstrated higher pump speeds are associated with hemolysis and a number of other adverse clinical outcomes \[[@B100-jcm-08-00981]\]. To prevent hemolysis-mediated kidney injury, it is suggested to limit pump revolutions/min (RPM) to safe levels (i.e., 3000 to 3500 RPM) in order to avoid excessive negative pressures generated within the pump \[[@B101-jcm-08-00981]\]. Future prospective studies are required to assess the effects of ECMO pump speed on AKI risk in ECMO patients. In addition, future studies creating risk prediction models for ECMO-associated AKI are needed to assist with the prevention of AKI in a timely manner, which could potentially lead to an improvement in patient survival.

Our study has several limitations. Firstly, there are statistical heterogeneities in our meta-analysis. Potential sources for heterogeneities were the variations in patient characteristics among the included studies. However, we performed subgroup analysis to assess the AKI incidence based on types of ECMO and a separate meta-analysis that only included studies with confounder-adjusted analysis for mortality risk. Another limitation was that AKI diagnosis was mainly based on serum creatinine \[[@B102-jcm-08-00981],[@B103-jcm-08-00981],[@B104-jcm-08-00981]\] while the data on urine output and novel biomarkers for AKI \[[@B105-jcm-08-00981],[@B106-jcm-08-00981],[@B107-jcm-08-00981],[@B108-jcm-08-00981]\] were limited. Lastly, this systematic review is primarily based on observational studies, as the data from clinical trials or population-based studies were limited. Therefore, it can at best, demonstrate an association but not a causal relationship.

5. Conclusions {#sec5-jcm-08-00981}
==============

In conclusion, there is an overall high incidence of AKI and severe AKI requiring RRT in ECMO patients of 62.8% and 44.9%, respectively. The incidence of ECMO-associated AKI has not changed over time. AKI requiring RRT while on ECMO is associated with 3.7-fold increased risk of hospital mortality. Future studies should focus on strategies for prediction, detection, and prevention of AKI among patients who receive ECMO.
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![Forest plots of the included studies assessing (**A**) incidence rates of AKI while on ECMO and (**B**) incidence rate of severe AKI requiring RRT while on ECMO. A diamond data marker depicts the overall rate from each included study (square data marker) and 95%CI.](jcm-08-00981-g002){#jcm-08-00981-f002}

![Meta-regression analyses showed that year of the study did not significantly affect (**A**) the incidence of AKI (*p* = 0.67) or (**B**) AKI requiring RRT (*p* = 0.83). The solid black line depicts the weighted regression line based on variance-weighted least squares. The inner and outer lines represent the 95%CI and prediction interval encompassing the regression line. The circles indicate log event rates in individual study.](jcm-08-00981-g003){#jcm-08-00981-f003}

![Forest plots of the included studies assessing (**A**) mortality rate of patients with AKI while on ECMO and (**B**) mortality rate of patients with severe AKI requiring RRT while on ECMO. A diamond data label serves as the overall rate from each study (square data marker) and 95%CI.](jcm-08-00981-g004){#jcm-08-00981-f004}

![Forest plots of the included studies assessing (**A**) hospital mortality among patients receiving ECMO with AKI on RRT and (**B**) hospital mortality among patients receiving ECMO with AKI on RRT limited to studies with confounder-adjusted analysis. A diamond data label serves as the overall rate from each included study (square data marker) and 95%CI.](jcm-08-00981-g005){#jcm-08-00981-f005}

![Meta-regression analyses showed that year of the study did not significantly affect hospital mortality among patients receiving ECMO with AKI requiring RRT (*p* = 0.86). The solid black line depicts the weighted regression line based on variance-weighted least squares. The inner and outer lines represent the 95%CI and prediction interval encompassing the regression line. The circles indicate log event rates in an individual study.](jcm-08-00981-g006){#jcm-08-00981-f006}

![Funnel plot demonstrated no publication bias in analyses evaluating (**A**) incidence of AKI in patients requiring ECMO and (**B**) severe AKI requiring RRT.](jcm-08-00981-g007){#jcm-08-00981-f007}

jcm-08-00981-t001_Table 1

###### 

Main characteristic of studies included in this meta-analysis of AKI incidence and mortality among patients requiring ECMO \[[@B7-jcm-08-00981],[@B15-jcm-08-00981],[@B29-jcm-08-00981],[@B30-jcm-08-00981],[@B31-jcm-08-00981],[@B32-jcm-08-00981],[@B33-jcm-08-00981],[@B34-jcm-08-00981],[@B35-jcm-08-00981],[@B36-jcm-08-00981],[@B37-jcm-08-00981],[@B38-jcm-08-00981],[@B39-jcm-08-00981],[@B40-jcm-08-00981],[@B41-jcm-08-00981],[@B42-jcm-08-00981],[@B43-jcm-08-00981],[@B44-jcm-08-00981],[@B45-jcm-08-00981],[@B46-jcm-08-00981],[@B47-jcm-08-00981],[@B48-jcm-08-00981],[@B49-jcm-08-00981],[@B50-jcm-08-00981],[@B51-jcm-08-00981],[@B52-jcm-08-00981],[@B53-jcm-08-00981],[@B54-jcm-08-00981],[@B55-jcm-08-00981],[@B56-jcm-08-00981],[@B57-jcm-08-00981],[@B58-jcm-08-00981],[@B59-jcm-08-00981],[@B60-jcm-08-00981],[@B61-jcm-08-00981],[@B62-jcm-08-00981],[@B63-jcm-08-00981],[@B64-jcm-08-00981],[@B65-jcm-08-00981],[@B66-jcm-08-00981],[@B67-jcm-08-00981]\].

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                          Year   Country     Patients                                                                     Number   AKI Definition                                 AKI Incidence        Mortality
  ---------------------------------------------- ------ ----------- ---------------------------------------------------------------------------- -------- ---------------------------------------------- -------------------- ---------------------------
  Pagani et al. \[[@B15-jcm-08-00981]\]          2001   USA         ECMO for cardiogenic shock or arrest                                         33       RRT                                            RRT\                 Hospital mortality\
                                                                                                                                                                                                         10/33 (30.3%)        9/10 (90%)

  Yap et al. \[[@B29-jcm-08-00981]\]             2003   Taiwan      ECMO for cardiogenic shock                                                   10       RRT                                            RRT\                 Mortality\
                                                                                                                                                                                                         5/10 (50%)           5/5 (100%)

  Lin et al. \[[@B30-jcm-08-00981]\]             2006   Taiwan      ECMO                                                                         46       AKI; RIFLE criteria                            AKI\                 AKI: Hospital mortality\
                                                                                                                                                                                                         36/46 (78.3%)\       28/36 (78%)\
                                                                                                                                                                                                         CRRT\                CRRT: Hospital mortality\
                                                                                                                                                                                                         16/46 (34.8%)        16/16 (100%)

  Tsai et al. \[[@B31-jcm-08-00981]\]            2008   Taiwan      ECMO                                                                         288      CRRT                                           CRRT\                Hospital mortality\
                                                                                                                                                                                                         104/288 (36.1%)      79/104 (76%)

  Bakhtiary et al. \[[@B32-jcm-08-00981]\]       2008   Germany     VA-ECMO for refractory cardiogenic shock                                     45       CRRT                                           CRRT\                N/A
                                                                                                                                                                                                         39/45 (86.7%)        

  Luo et al. \[[@B33-jcm-08-00981]\]             2009   China       VA-ECMO in severe heart failure                                              45       CRRT                                           CRRT\                Hospital mortality\
                                                                                                                                                                                                         12/45 (26.6%)        7/9 (78%)

  Brogan et al. \[[@B34-jcm-08-00981]\]          2009   USA         ECMO in severe respiratory failure                                           1473     RRT                                            RRT\                 Hospital mortality\
                                                                                                                                                                                                         648/1473 (44%)       RRT\
                                                                                                                                                                                                                              390/648 (60%)

  Wang et al. \[[@B35-jcm-08-00981]\]            2009   China       VA ECMO for refractory cardiogenic shock after cardiac surgery               62       CRRT                                           CRRT\                N/A
                                                                                                                                                                                                         23/62 (37.0%)        

  Yan et al. \[[@B36-jcm-08-00981]\]             2010   China       ECMO after cardiac surgery                                                   67       AKI; RIFLE and AKIN criteria                   RIFLE AKI\           Hospital mortality\
                                                                                                                                                                                                         54/67 (80.6%)\       RIFLE AKI\
                                                                                                                                                                                                         AKIN AKI\            32/54 (59%)\
                                                                                                                                                                                                         57/67 (85.1%)\       AKIN AKI\
                                                                                                                                                                                                         RRT\                 33/57 (58%)\
                                                                                                                                                                                                         30/67 (44.8%)        RRT\
                                                                                                                                                                                                                              22/30 (73%)

  Elsharkawy et al. \[[@B37-jcm-08-00981]\]      2010   USA         VA-ECMO after cardiac surgery                                                233      RRT                                            RRT\                 Hospital mortality\
                                                                                                                                                                                                         101/233 (43.3%)      79/101 (78%)

  Hsu et al. \[[@B38-jcm-08-00981]\]             2010   Taiwan      VA-ECMO for cardiogenic shock after cardiac surgery                          51       CRRT                                           CRRT\                N/A
                                                                                                                                                                                                         38/51 (74.5%)        

  Lan et al. \[[@B39-jcm-08-00981]\]             2010   Taiwan      ECMO                                                                         607      RRT                                            RRT\                 Hospital mortality\
                                                                                                                                                                                                         301/607 (49.6%)      259/301 (86%)

  Rastan et al. \[[@B40-jcm-08-00981]\]          2010   Germany     VA-ECMO for cardiogenic shock after cardiac surgery                          517      RRT                                            RRT\                 N/A
                                                                                                                                                                                                         336/517 (65.0%)      

  Wu et al. \[[@B41-jcm-08-00981]\]              2010   Taiwan      ECMO                                                                         346      RRT                                            RRT\                 RRT\
                                                                                                                                                                                                         187/346 (54%)        72/102 (71%)

  Chen et al. \[[@B42-jcm-08-00981]\]            2011   Taiwan      ECMO                                                                         102      AKI; AKIN criteria                             AKI\                 Hospital mortality\
                                                                                                                                                                                                         62/102 (60.8%)\      AKI\
                                                                                                                                                                                                         CRRT\                51/62 (82%)\
                                                                                                                                                                                                         26/102 (25.5%)       CRRT\
                                                                                                                                                                                                                              22/26 (85%)

  Bermudez et al. \[[@B43-jcm-08-00981]\]        2011   USA         ECMO for refractory cardiogenic shock; VA (88%)                              42       RRT                                            RRT\                 N/A
                                                                                                                                                                                                         17/42 (40.5%)        

  Chang et al. \[[@B44-jcm-08-00981]\]           2012   Taiwan      Successfully weaned from ECMO                                                113      AKI; AKIN criteria at 48 h post-ECMO removal   AKI\                 Hospital mortality\
                                                                                                                                                                                                         51/113 (45.1%)       AKI\
                                                                                                                                                                                                                              23/51 (45%)

  Kim et al. \[[@B45-jcm-08-00981]\]             2012   Korea       ECMO; VA-ECMO (85%), VV-ECMO (15%)                                           26       AKI; AKIN criteria                             AKI\                 N/A
                                                                                                                                                                                                         10/26 (38.5%)        

  Lee et al. \[[@B46-jcm-08-00981]\]             2012   Korea       ECMO; VA-ECMO (74%), VV-ECMO (26%)                                           185      CRRT                                           CRRT\                N/A
                                                                                                                                                                                                         76/185 (41.1%)       

  Loforte et al. \[[@B47-jcm-08-00981]\]         2012   Italy       VA-ECMO                                                                      73       CRRT                                           CRRT\                N/A
                                                                                                                                                                                                         38/73 (52.1%)        

  Wu et al. \[[@B48-jcm-08-00981]\]              2012   Taiwan      ECMO for non-post cardiotomy cardiogenic shock or cardiac arrest             60       RRT                                            RRT\                 Hospital mortality\
                                                                                                                                                                                                         19/60 (31.7%)        13/19 (68%)

  Aubron et al. \[[@B49-jcm-08-00981]\]          2013   Australia   ECMO; VA-ECMO (67%), VV-ECMO (33%)                                           158      RRT                                            VA-ECMO\             Hospital mortality\
                                                                                                                                                                                                         RRT\                 VA-ECMO\
                                                                                                                                                                                                         61/105 (58.1%)\      RRT\
                                                                                                                                                                                                         VV-ECMO\             27/61 (44%)\
                                                                                                                                                                                                         RRT\                 VV-ECMO\
                                                                                                                                                                                                         27/53 (50.9%)        RRT\
                                                                                                                                                                                                                              13/27 (48%)

  Kielstein et al. \[[@B50-jcm-08-00981]\]\      2013   Germany     ECMO; VA-ECMO (45%), VV-ECMO (55%)                                           200      RRT                                            RRT\                 90-day mortality\
                                                                                                                                                                                                         117/200 (58.5%)\     97/117 (83%)
                                                                                                                                                                                                         RRT after ECMO\      
                                                                                                                                                                                                         92/175 (52.6%)       

  Wu et al. \[[@B51-jcm-08-00981]\]              2013   Taiwan      ECMO for acute myocardial infarction-induced cardiac arrest                  35       RRT                                            RRT\                 Hospital mortality\
                                                                                                                                                                                                         16/35 (45.7%)        14/16 (88%)

  Lazzeri et al. \[[@B52-jcm-08-00981]\]         2013   Italy       ECMO for refractory cardiac arrest                                           25       RRT                                            RRT\                 Mortality\
                                                                                                                                                                                                         16/24 (66.7%)        9/16 (56%)

  Unosawa et al. \[[@B53-jcm-08-00981]\]         2013   Japan       VA-ECMO for refractory cardiogenic shock after cardiac surgery               47       RRT                                            RRT\                 Mortality on ECMO\
                                                                                                                                                                                                         15/47 (31.9%)        7/15 (46.7%)

  Xue et al. \[[@B54-jcm-08-00981]\]             2014   China       ECMO in lung transplantation                                                 45       AKI; AKIN criteria                             AKI\                 N/A
                                                                                                                                                                                                         17/45 (37.8%)        

  Schmidt et al. \[[@B7-jcm-08-00981]\]          2014   Australia   ECMO for refractory cardiogenic shock or acute respiratory failure           172      AKI; RIFLE criteria\                           AKI at ECMO day 1\   90-day mortality\
                                                                                                                                                                                                         98/172 (57.0%)\      CRRT\
                                                                                                                                                                                                         CRRT during ECMO\    34/103 (33%)
                                                                                                                                                                                                         103/172 (59.9%)      

  Hsiao et al. \[[@B55-jcm-08-00981]\]           2014   Taiwan      ECMO for ARDS                                                                81       CRRT                                           CRRT\                Hospital mortality\
                                                                                                                                                                                                         33/81 (40.7%)        CRRT\
                                                                                                                                                                                                                              22/33 (67%)

  Lee et al. \[[@B56-jcm-08-00981]\]             2015   Korea       ECMO; VA-ECMO (71%), VV-ECMO (29%)                                           322      AKI; KDIGO criteria                            AKI\                 Hospital mortality\
                                                                                                                                                                                                         265/322 (82.3%)      151/265 (57%)

  Haneya \[[@B57-jcm-08-00981]\]                 2015   Germany     VV-ECMO for ARDS                                                             262      AKI; KDIGO criteria                            AKI\                 Mortality\
                                                                                                                                                                                                         109/262 (41.6%)\     AKI\
                                                                                                                                                                                                         RRT during ECMO\     56/109 (51%)\
                                                                                                                                                                                                         52/262 (19.8%)       RRT during ECMO\
                                                                                                                                                                                                                              23/52 (44%)

  Huang et al. \[[@B58-jcm-08-00981]\]           2016   China       ECMO for acute respiratory distress syndrome; VA-ECMO (17%), VV-ECMO (83%)   23       AKI; AKIN criteria                             AKI\                 Mortality\
                                                                                                                                                                                                         13/23 (56.5%)        9/13 (69%)

  Antonucci et al. \[[@B59-jcm-08-00981]\]       2016   Belgium     ECMO; VA-ECMO (59%), VV-ECMO (41%)                                           135      AKI; AKIN criteria                             AKI\                 ICU mortality\
                                                                                                                                                                                                         95/135 (70.4%)\      AKI\
                                                                                                                                                                                                         CRRT\                55/95 (58%)\
                                                                                                                                                                                                         63/135 (46.7%)       CRRT\
                                                                                                                                                                                                                              38/63 (60%)

  Tsai et al. \[[@B60-jcm-08-00981]\]            2017   Taiwan      ECMO                                                                         167      AKI; RIFLE, AKIN and KDIGO on ECMO day 1       RIFLE AKI\           Hospital mortality\
                                                                                                                                                                                                         126/167 (75.4%)\     RIFLE AKI\
                                                                                                                                                                                                         AKIN AKI\            85/126 (67%)\
                                                                                                                                                                                                         141/167 (84.4%)\     AKIN AKI\
                                                                                                                                                                                                         KDIGO AKI\           90/126 (71%)\
                                                                                                                                                                                                         142/167 (85.0%)      RIFLE AKI\
                                                                                                                                                                                                                              90/126 (71%)

  Panholzer et al. \[[@B61-jcm-08-00981]\]       2017   Germany     VV-ECMO for ARDS                                                             46       RRT                                            RRT\                 Mortality\
                                                                                                                                                                                                         31/46 (67.4%)        RRT\
                                                                                                                                                                                                                              23/31 (74%)

  Chong et al. \[[@B62-jcm-08-00981]\]           2018   Taiwan      VA-ECMO for acute fulminant myocarditis and cardiogenic shock                35       AKI; not specified                             AKI\                 Hospital mortality\
                                                                                                                                                                                                         26/35 (74.3%)\       AKI\
                                                                                                                                                                                                         RRT\                 14/26 (54%)\
                                                                                                                                                                                                         15/35 (42.9%)        RRT\
                                                                                                                                                                                                                              11/15 (73%)

  Devasagayaraj et al. \[[@B63-jcm-08-00981]\]   2018   USA         VV-ECMO for ARDS                                                             54       CRRT                                           CRRT\                Hospital mortality\
                                                                                                                                                                                                         16/54 (29.6%)        9/16 (56%)

  Liao et al. \[[@B64-jcm-08-00981]\]            2018   China       ECMO; VA-ECMO (93%), VV-ECMO (7%)                                            170      AKI; KDIGO criteria                            AKI\                 N/A
                                                                                                                                                                                                         91/170 (53.5%)       

  Paek et al. \[[@B65-jcm-08-00981]\]            2018   Korea       ECMO                                                                         538      CRRT                                           CRRT\                30-day mortality\
                                                                                                                                                                                                         296/838 (35.3%)      195/296 (66%)

  He et al. \[[@B66-jcm-08-00981]\]              2018   China       ECMO                                                                         92       CRRT                                           CRRT\                Hospital mortality\
                                                                                                                                                                                                         32/92 (34.8%)        19/32 (59%)

  Chen et al. \[[@B67-jcm-08-00981]\]            2019   Taiwan      ECMO                                                                         3251     RRT                                            RRT\                 Hospital mortality\
                                                                                                                                                                                                         1759/3251 (54.1%)    1298/1759 (74%)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; AKIN, Acute Kidney Injury Network; CRRT, continuous renal replacement therapy; ECMO, Extracorporeal membrane oxygenation; ICU, intensive care unit; KDIGO, Kidney Disease Improving Global Outcomes; N/A, not available; RIFLE, Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease; RRT, Renal replacement therapy; USA, United States of America; VA-ECMO, venoarterial extracorporeal membrane oxygenation; VV-ECMO, venovenous extracorporeal membrane oxygenation.
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###### 

Characteristics of studies included in this meta-analysis of AKI associated mortality risk among patients requiring ECMO.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study.                                         Year   Number   Outcomes                                          Confounder Adjustment
  ---------------------------------------------- ------ -------- ------------------------------------------------- ------------------------------------------------------------------------------------------------------------------
  Pagani et al. \[[@B15-jcm-08-00981]\]          2001   33       Hospital mortality\                               None
                                                                 8.25 (0.89--76.12)                                

  Lin et al. \[[@B30-jcm-08-00981]\]             2006   46       Hospital mortality\                               None
                                                                 AKI: 14.0 (2.46--79.55)\                          
                                                                 CRRT: 16/16 vs. 14/30                             

  Luo et al. \[[@B33-jcm-08-00981]\]             2009   45       Hospital mortality\                               None
                                                                 CRRT: 7.0 (1.26--38.99)                           

  Brogan et al. \[[@B34-jcm-08-00981]\]          2009   1473     Hospital mortality\                               Age, duration of mechanical ventilation, weight, pre-ECMO pH, race, diagnosis, ECMO mode, post-ECMO complication
                                                                 Renal insufficiency/failure: 2.13 (1.69--2.72)\   
                                                                 RRT: 2.13 (1.73--2.63)                            

  Elsharkawy et al. \[[@B37-jcm-08-00981]\]      2010   233      Hospital mortality\                               None
                                                                 RRT: 3.18 (1.77--5.70)                            

  Yan et al. \[[@B36-jcm-08-00981]\]             2010   67       Hospital mortality\                               None
                                                                 RIFLE AKI: 8.0 (1.61--39.68)\                     
                                                                 AKIN AKI: 12.38 (1.47--104.33)\                   
                                                                 CRRT: 5.73 (1.98--16.58)                          

  Lan et al. \[[@B39-jcm-08-00981]\]             2010   607      Hospital mortality\                               Age, stroke, pre-ECMO infection, hypoglycemia, alkalosis
                                                                 RRT: 6.49 (4.12--10.23)                           

  Chen et al. \[[@B67-jcm-08-00981]\]            2011   102      Hospital mortality\                               Age, GCS
                                                                 AKI: 4.32 (1.65--11.30)\                          
                                                                 CRRT: 5.80 (1.82--18.43)                          

  Chang et al. \[[@B44-jcm-08-00981]\]           2012   113      Hospital mortality\                               None
                                                                 AKI: 2.1 (1.48--3.00)                             

  Wu et al. \[[@B48-jcm-08-00981]\]              2012   60       Hospital mortality\                               None
                                                                 RRT: 3.76 (1.18--11.95)                           

  Kielstein et al. \[[@B50-jcm-08-00981]\]       2013   200      90-day mortality\                                 None
                                                                 RRT: 5.47(2.87--10.44)                            

  Aubron et al. \[[@B49-jcm-08-00981]\]          2013   158      VA ECMO\                                          None
                                                                 RRT: 2.12 (0.92--4.88)\                           
                                                                 VV ECMO\                                          
                                                                 RRT: 2.52 (0.80--7.95)                            

  Wu et al. \[[@B51-jcm-08-00981]\]              2013   35       Hospital mortality\                               None
                                                                 RRT: 12 (2.08--69.09)                             

  Slottosch et al. \[[@B23-jcm-08-00981]\]       2013   77       30-day mortality\                                 None
                                                                 Renal failure: 2.20 (0.78--6.12)                  

  Unosawa et al. \[[@B53-jcm-08-00981]\]         2013   47       Mortality during ECMO\                            None
                                                                 RRT: 1.67 (0.48--5.83)                            

  Lazzeri et al. \[[@B52-jcm-08-00981]\]         2013   25       Mortality\                                        None
                                                                 RRT: 2.14 (0.38--12.20)                           

  Hsiao et al. \[[@B55-jcm-08-00981]\]           2014   81       Hospital mortality\                               None
                                                                 CRRT: 2.17 (0.87--5.45)                           

  Schmidt et al. \[[@B7-jcm-08-00981]\]          2014   172      Hospital mortality\                               APACHE, fluid balance, major bleeding, propensity score
                                                                 CRRT at ECMO day 1--3: 4.1 (1.71--9.82)\          
                                                                 90-day mortality\                                 
                                                                 CRRT at ECMO day 1--3: 3.17 (1.32--7.61)          

  Lee et al. \[[@B56-jcm-08-00981]\]             2015   322      Hospital mortality\                               None
                                                                 AKI: 3.71 (1.96--7.02)                            

  Haneya et al. \[[@B57-jcm-08-00981]\]          2015   262      Mortality\                                        Age, SOFA score, minute volume, pH, lactate, RRT prior to ECMO, RBC, and FFP transfusion
                                                                 AKI: 2.18 (1.31--3.61)\                           
                                                                 RRT during ECMO: 1.72 (0.53--5.59)                

  Huang et al. \[[@B58-jcm-08-00981]\]           2016   23       Mortality\                                        None
                                                                 AKI: 20.25 (1.88--218.39)                         

  Lyu et al. \[[@B27-jcm-08-00981]\]             2016   84       Mortality\                                        None
                                                                 ARF: 23.90 (7.00--81.60)                          

  Antonucci et al. \[[@B59-jcm-08-00981]\]       2016   135      ICU mortality\                                    None
                                                                 AKI: 1.86 (0.88--3.93)\                           
                                                                 CRRT: 1.70 (0.85--3.37)                           

  Tsai et al. \[[@B60-jcm-08-00981]\]            2017   167      Hospital mortality\                               None
                                                                 RIFLE AKI: 8.55 (3.63--20.16)\                    
                                                                 AKIN AKI: 13.53 (3.87--47.28)\                    
                                                                 KDIGO AKI: 12.69 (3.62--44.46)                    

  Panholzer et al. \[[@B61-jcm-08-00981]\]       2017   46       Mortality\                                        None
                                                                 RRT: 40.25 (4.54--356.93)                         

  Martucci et al. \[[@B28-jcm-08-00981]\]        2017   82       Mortality on ECMO\                                None
                                                                 AKI stage 3: 4.55 (1.37--15.17)                   

  Chong et al. \[[@B62-jcm-08-00981]\]           2018   35       Hospital mortality\                               None
                                                                 AKI: 9.33 (1.02--85.70)\                          
                                                                 RRT: 11.0 (2.26--53.64)                           

  Devasagayaraj et al. \[[@B63-jcm-08-00981]\]   2018   54       Hospital mortality\                               None
                                                                 RRT: 5.69 (1.58--20.56)                           

  Chen et al. \[[@B67-jcm-08-00981]\]            2019   3,251    Hospital mortality\                               Age, sex, ECMO indication, comorbid conditions, hospital level, study year
                                                                 RRT: 3.92 (3.36--4.57)                            
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; AKIN, Acute Kidney Injury Network; APACHE, Acute Physiology and Chronic Health Evaluation; CRRT, continuous renal replacement therapy; ECMO, Extracorporeal membrane oxygenation; FFP, fresh frozen plasma; GCS, Glasgow Coma Scale/Score; ICU, intensive care unit; KDIGO, Kidney Disease Improving Global Outcomes; N/A, not available; RIFLE, Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease; RBC, red blood cells; RRT, Renal replacement therapy; pH, potential hydrogen; SOFA, Sequential Organ Failure Assessment; VA-ECMO, venoarterial extracorporeal membrane oxygenation; VV-ECMO, venovenous extracorporeal membrane oxygenation.
